Frédéric Rolland

23.6k total citations · 5 hit papers
142 papers, 11.6k citations indexed

About

Frédéric Rolland is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Frédéric Rolland has authored 142 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Pulmonary and Respiratory Medicine, 55 papers in Oncology and 42 papers in Surgery. Recurrent topics in Frédéric Rolland's work include Renal cell carcinoma treatment (53 papers), Head and Neck Cancer Studies (31 papers) and Renal and related cancers (25 papers). Frédéric Rolland is often cited by papers focused on Renal cell carcinoma treatment (53 papers), Head and Neck Cancer Studies (31 papers) and Renal and related cancers (25 papers). Frédéric Rolland collaborates with scholars based in France, United States and Germany. Frédéric Rolland's co-authors include Bernard Escudier, Sylvie Négrier, Stéphane Oudard, Christine Chevreau, Tomasz Demkow, Thomas E. Hutson, Ronald M. Bukowski, Cezary Szczylik, Martin Gore and Apurva A. Desai and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Frédéric Rolland

139 papers receiving 11.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 3.8k citations Bernard Escudier, Tim Eisen et al. profile →
Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer

2004 2.2k citations Frédéric Rolland et al. profile →
Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

2009 864 citations Bernard Escudier, Tim Eisen et al. Journal of Clinical Oncology profile →
Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

2007 734 citations Frédéric Rolland et al. Journal of Clinical Oncology profile →
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

2015 315 citations Gwénaëlle Gravis, Florence Joly et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Frédéric Rolland	6.7k	4.8k	4.3k	3.0k	2.7k	142	11.6k
Nadia Amellal	4.0k 0.6×	2.1k 0.4×	5.3k 1.2×	847 0.3×	2.4k 0.9×	60	9.0k
Tarek Sahmoud	4.9k 0.7×	2.1k 0.4×	5.1k 1.2×	1.8k 0.6×	3.1k 1.1×	130	11.3k
Fernando Rivera	4.7k 0.7×	1.9k 0.4×	10.2k 2.4×	1.6k 0.5×	2.6k 0.9×	168	12.9k
Lori J. Wirth	2.4k 0.4×	2.0k 0.4×	4.3k 1.0×	961 0.3×	1.8k 0.7×	260	9.9k
Ihor Vynnychenko	4.3k 0.6×	1.4k 0.3×	4.6k 1.1×	901 0.3×	1.4k 0.5×	57	7.0k
Gilberto de Castro	5.4k 0.8×	1.5k 0.3×	8.0k 1.9×	1.8k 0.6×	943 0.3×	215	10.7k
Christopher U. Jones	5.2k 0.8×	1.5k 0.3×	3.7k 0.9×	802 0.3×	3.3k 1.2×	68	10.3k
Federica Perrone	2.7k 0.4×	2.1k 0.5×	3.6k 0.8×	1.3k 0.4×	2.0k 0.7×	235	7.9k
Didier Cupissol	4.4k 0.7×	1.6k 0.3×	4.9k 1.1×	543 0.2×	2.5k 0.9×	160	8.9k
Junming Zhu	4.3k 0.6×	1.8k 0.4×	4.1k 1.0×	879 0.3×	941 0.3×	29	7.3k

Countries citing papers authored by Frédéric Rolland

Since Specialization

Citations

This map shows the geographic impact of Frédéric Rolland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Rolland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Rolland more than expected).

Fields of papers citing papers by Frédéric Rolland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Rolland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Rolland. The network helps show where Frédéric Rolland may publish in the future.

Co-authorship network of co-authors of Frédéric Rolland

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Rolland. A scholar is included among the top collaborators of Frédéric Rolland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Rolland. Frédéric Rolland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fizazi, Karim, Gwénaël Le Teuff, Aude Fléchon, et al.. (2024). Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Journal of Clinical Oncology. 42(28). 3270–3276. 4 indexed citations

Gross‐Goupil, Marine, Éric Frison, Guilhem Roubaud, et al.. (2024). GCISAVE: A non-comparative randomized phase II study of combination of gemcitabine cisplatin (GCis) +/- avelumab (A) in 1st line treatment for locally advanced or metastatic urothelial bladder carcinoma (MUBC)—GETUG AFU V07.. Journal of Clinical Oncology. 42(4_suppl). 637–637. 1 indexed citations

Fayette, Jérôme, Caroline Even, Laurence Digue, et al.. (2023). NISCAHN: a phase II trial of nivolumab in patients with salivary gland carcinoma (Unicancer ORL-08). SHILAP Revista de lepidopterología. 2(1). e000065–e000065. 6 indexed citations

Rioux‐Leclercq, Nathalie, Maxime Meylan, Christophe Passot, et al.. (2023). Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 11(11). e006885–e006885. 8 indexed citations

Tourneau, Christophe Le, Frédéric Rolland, Olivier Capitain, et al.. (2023). Immunogenicity and clinical activity of tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: A randomized phase 2 study in advanced anogenital cancers.. Journal of Clinical Oncology. 41(16_suppl). 2630–2630.

Guerlain, Joanne, Nathalie Cozic, Amaury Daste, et al.. (2023). 855MO Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1). Annals of Oncology. 34. S557–S557. 3 indexed citations

Thibault, Constance, Aude Fléchon, Laurence Albigès, et al.. (2023). Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24). European Journal of Cancer. 186. 83–90. 12 indexed citations

Galot, Rachel, Christophe Le Tourneau, Lisa Licitra, et al.. (2023). 935P A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM). Annals of Oncology. 34. S588–S589. 2 indexed citations

Campion, L., Valérie Seegers, Oana Cojocarasu, et al.. (2023). Geriatric Assessment Implementation before Chemotherapy in MEtastatic Prostate Cancer, Results from the Real-Life Study GAMERS. Journal of Clinical Medicine. 12(4). 1636–1636. 2 indexed citations

10.

Grünwald, Viktor, Thomas Powles, Evgeny Kopyltsov, et al.. (2023). Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. European Urology Oncology. 6(4). 437–446. 16 indexed citations

11.

Colomba, Émeline, Luca Campedel, Clément Dumont, et al.. (2022). Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study. Cancers. 14(7). 1678–1678. 7 indexed citations

12.

Derosa, Lisa, Cécile Dalban, Émeline Colomba, et al.. (2021). 697P Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N). Annals of Oncology. 32. S710–S710. 5 indexed citations

13.

Thibault, Constance, Aude Fléchon, Laurence Albigès, et al.. (2020). 724P A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial). Annals of Oncology. 31. S568–S568. 6 indexed citations

14.

Barthélémy, Philippe, Clément Dumont, Brigitte Laguerre, et al.. (2020). 735P Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study. Annals of Oncology. 31. S574–S574. 3 indexed citations

15.

Auclin, Édouard, Philippe Barthélémy, Petri Bono, et al.. (2019). Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European Journal of Cancer. 108. 33–40. 95 indexed citations

16.

Escudier, Bernard, Thomas Powles, Robert J. Motzer, et al.. (2018). Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. Journal of Clinical Oncology. 36(8). 765–772. 121 indexed citations

17.

Oudard, Stéphane, I. Latorzeff, Armelle Caty, et al.. (2017). Docetaxel (D) with androgen suppression (AS) for high-risk localized prostate cancer (HrPC) patients (pts) who relapsed PSA after radical prostatectomy (RP) and/or radiotherapy (RT): A randomized phase III trial. Annals of Oncology. 28. v269–v270. 3 indexed citations

18.

Escudier, Bernard, Cezary Szczylik, Thomas E. Hutson, et al.. (2009). Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(8). 1280–1289. 378 indexed citations

19.

Escudier, Bernard, Tim Eisen, Walter M. Stadler, et al.. (2009). Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Journal of Clinical Oncology. 27(20). 3312–3318. 864 indexed citations breakdown →

20.

Théry, C, et al.. (1977). [Atrioventricular block in rheumatoid polyarthritis. Histological study of His-Tawara system (apropos of a new case)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 22(2). 92–7.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact